1. 1501TiPAfatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSIME) failure for aDvanced EGFR-mutant non-small cell lung cancer (NSCLC): A multicenter prospective single arm phase II study (ABCD-study). (23rd October 2018) Authors: Hata, A; Katakami, N; Nishino, K; Mori, M; Yokoyama, T; Kurata, T; Tachihara, M; Takase, N; Daga, H; Kijima, T; Morita, S; Sakai, K; Nishio, K; Satouchi, M; Negoro, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 520PA phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116). (24th November 2019) Authors: Hata, A; Satouchi, M; Morita, S; Ota, Y; Urata, Y; Kawa, Y; Okada, H; Mayahara, H; Kokubo, M; Akazawa, Y; Uenami, T; Tamiya, M; Kunimasa, K; Nakata, K; Harada, D; Nakamura, A; Takase, N; Katakami, N; Negoro, S Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗